Wei Zhou

Dr. Wei Zhou

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in The American Journal of Surgery
Verified
Journal Article
Closed access
WZWei Zhou
Wei Zhou
RLRan Lv
Ran Lv
XWXianfa Wang
Xianfa Wang
YMYiping Mou
Yiping Mou
XCXiujun Cai
Xiujun Cai
IHIngrid Herr
Ingrid Herr

10 July 2018 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
XGXiaolong Ge
Xiaolong Ge
JPJunhai Pan
Junhai Pan
YLYichang Liu
Yichang Liu
HWHongkan Wang
Hongkan Wang
WZWei Zhou
Wei Zhou
XWXianfa Wang
Xianfa Wang
Background: The gastrointestinal tract harbours a diverse bacterial community that contributes to health and disease. A number of studies have demonstrated that the gut microbiota plays a critical role in the metabolism of serotonin. Methods: Microbial-derived metabolites, such as bile acids and short-chain fatty acids, are reported to affect the production of serotonin which, in turn, directly or indirectly regulates gut motility. Enterochromaffin cells are important specialized endocrine cells found in the intestine, which is the major location of serotonin biosynthesis. The relationship between microbiota and gut motility are studied depended on microbial-derived metabolites and serotonin. Results and conclusion: Both bile acids and short-chain fatty acids can modulate serotonin metabolism in hosts by affecting key intermediates of the serotonin pathway. Thus, gut motility may be regulated through microbial modifications of host serotonin biosynthesis, which continues to be evaluated as a target for functional gastrointestinal disorders.

1 May 2019 in International Journal of Surgery
Verified
Journal Article
Closed access
XGXiaolong Ge
Xiaolong Ge
STShasha Tang
Shasha Tang
XYXiaoyan Yang
Xiaoyan Yang
WLWei Liu
Wei Liu
LYLinna Ye
Linna Ye
XCXiujun Cai
Xiujun Cai
Growing evidence has shown that there are significant advantages associated with the use of laparoscopic surgery for Crohn's disease (CD). However, the impact of preoperative exclusive enteral nutrition (EEN) on postoperative complications and CD recurrence following laparoscopic surgery have not been investigated. A total of 120 CD patients undergoing bowel resection with laparoscopic surgery were eligible for this study. Patient data were collected from a prospectively maintained database. Before laparoscopic surgery, 45 CD patients received EEN for at least 4 weeks, and 75 CD patients had no EEN. Postoperative complications, and endoscopic and clinical recurrence were subsequently measured and compared after laparoscopic surgery and during follow-up assessments. Patients who received EEN had significant improvements in their nutritional (albumin, prognostic nutritional index (PNI), and hemoglobin) and inflammatory (C-reactive protein) status after the EEN treatment prior to surgery (P < 0.05). Patients who received EEN also experienced fewer postoperative complications, decreased surgical site infections, and a lower comprehensive complication index (P < 0.05). The endoscopic recurrence rates 6 months after surgery were also decreased significantly in patients who received EEN (P < 0.05). However, the incidence of clinical recurrence was similar in the 2 groups at 1-year follow-up. Endoscopic recurrence was correlated with ileocolonic disease, EEN before surgery, and PNI (P < 0.05). PNI remained independently associated with endoscopic recurrence after surgery. Preoperative EEN for at least 4 weeks improved CD patients' nutritional and inflammatory status, which in turn reduced postoperative complications following laparoscopic surgery and endoscopic recurrence on follow-up.

21 February 2020 in Trials
Verified
Journal Article
Open access
PDF file
YLYi Li
Yi Li
HMHelen Mohan
Helen Mohan
NLNan Lan
Nan Lan
XWXiaojian Wu
Xiaojian Wu
WZWei Zhou
Wei Zhou
WZWeiming Zhu
Weiming Zhu
Background: The structures of the mesentery including adipose tissue, nerves, and lymphatics play an important role in the pathogenesis and disease progression of Crohn’s disease (CD). Conventional surgical resection for CD usually does not involve resecting the mesentery en bloc with the specimen. This contrasts with complete mesocolic excision (CME) in colorectal cancer, which involves radical resection of the mesentery. Preliminary evidence from smaller studies suggests that applying the principle of mesocolic excision to CD surgery may reduce the risk of postoperative recurrence. This randomized controlled trial is designed to test whether applying the principles of mesocolic excision to CD results in reduced postoperative recurrence. It also aims to evaluate intra- and postoperative morbidity between the two approaches. Methods: This international, multicenter, randomized controlled trial will randomize patients (n = 116) scheduled to undergo primary ileocolic resection to either receive extensive mesenteric excision (EME) or conventional ileocolic resection with limited mesenteric excision (LME). Five sites will recruit patients in three countries. In the EME group, the mesentery is resected following CME, while avoiding the root region, i.e., 1 cm from the root of the ileocolic artery and vein. In the LME group, the mesentery is retained, i.e., “close shave” or < 3 cm from the border of bowel. The primary end point will be surgical recurrence after surgery. The secondary end points will be the postoperative endoscopic and clinical recurrence, and intra- and postoperative morbidity. Demographics, risk factors, laboratory investigations, endoscopy, postoperative prophylaxis and imaging examination will be assessed. Analysis of the primary outcome will be on an intention-to-treat basis. Discussion: If mesocolic excision in CD reduces postoperative disease recurrence and does not increase morbidity, this trial has the potential to change practice and reduce recurrence of CD after surgical resection. Trial registration: Clinical Trials.gov, ID: NCT03769922. Registered on February 27, 2019.

15 March 2018 in Disease Markers
Verified
Journal Article
Open access
PDF file
DYDongdong Yu
Dongdong Yu
YCYikai Cai
Yikai Cai
WZWei Zhou
Wei Zhou
JSJinghao Sheng
Jinghao Sheng
ZXZhengping Xu
Zhengping Xu
Background. Angiogenin (ANG) is a multifunctional angiogenic protein that participates in both normal development and diseases. Abnormal serum ANG levels are commonly reported in various diseases. However, whether ANG can serve as a diagnostic or prognostic marker for different diseases remains a matter of debate.Methods. Here, we performed a systematic review and meta-analysis of the literature utilizing PubMed, Web of Science, and Scopus search engines to identify all publications comparing plasma or serum ANG levels between patients with different diseases and healthy controls, as were studies evaluating circulating ANG levels in healthy populations, pregnant women, or other demographic populations.Results. This study demonstrated that the serum ANG concentration in healthy populations was 336.14 ± 142.83 ng/ml and remained relatively stable in different populations and regions. We noted no significant differences in serum ANG levels between patients and healthy controls, except in cases in which patients suffered from cancer or cardiovascular diseases. The serum ANG concentrations were significantly higher in patients who developed colorectal cancer, acute myeloid leukemia, multiple myeloma, myelodysplastic syndromes, and heart failure than those in healthy controls.Conclusion. ANG has the potential of being a serum biomarker for cancers and cardiovascular diseases.

1 September 2013 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
XXXiaowu Xu
Xiaowu Xu
KCKe Chen
Ke Chen
WZWei Zhou
Wei Zhou
RZRenchao Zhang
Renchao Zhang
JWJie Wang
Jie Wang
YMYiping Mou
Yiping Mou